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Abstract
Lymphoid neoplasms are a heterogeneous group of malignancies whose diagnosis 
depends on a very good analysis of hematopathology and morphology, immunophe-
notype, cytogenetic, molecular, and clinical characteristics. B-cell lymphomas begin 
from different developmental stages of B cells in germinal centers of secondary lym-
phoid tissue. The evolution of B-cell lymphomagenesis depends on different numbers 
of signal pathways. Proteins that play key point of signaling networks are changed by 
aberrant chromosomal expression, translocation, and/or accumulation, and those 
events determine the fate of the affected B cells. Many chemokines and cytokines have 
been implicated in providing the line for the cellular surviving and interaction in lym-
phoid organogenesis. Specific chromosomal alterations were associated with signifi-
cant changes in gene-expression signatures that reflect various aspects of lymphoma 
cell biology as well as the host response to the lymphoma. The goal of this study was to 
find out a correlation between tumor markers and survival in patients with subgroups 
of DLBCL. The goal is to find out chronic autoimmune or pathogen-induced immune 
reactions resulting in lymphoid neogenesis. So we address (i) chemokines and adhe-
sion molecules involved in lymphoid neogenesis, (ii) the autoimmune diseases and 
pathogens which are associated with the development of B-cell lymphomas, and (iii) 
the molecular mechanisms involved in the initiation and progression of DLBCL.
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1. Germinal center B-cell dynamics
Characteristic chromosome translocation is associated with certain entities 
of the disease that is known to play a key role in the development of lymphoma. 
Chromosomal translocation alone, however, is not sufficient for the appearance 
of a tumor. Various factors, including microenvironment, epigenetic, and genetic 
changes, play a role in the development of lymphomas. Follicular dendritic cells 
(FDC) produce high-affinity antibody needed for the development of B-cell 
memory. These cells can be detected in B-cell non-Hodgkin lymphomas (NHL). 
Gene-expression profiling revealed that the FDC network could affect the clinical 
outcome in DLBCL [1–3].
Transgenic mouse model with different genes linked to chromosomal translocations 
has shown that chromosomal translocation alone is not sufficient for the development 
of lymphoma [1]. Transgenic mice with the c-MYC (myelomatosis viral oncogene 
homolog) genome develop lymphoma after a long time. The c-MYC gene is located 
at 8q24 and is associated with the translocation t (8; 14) (q24; q32). This was the first 
recurring chromosome abnormality ever reported in lymphoproliferative disorders. 
C-MYC in place next to immunoglobulin heavy locus (IGH) results in the expression 
of c-Myc protein, which is a key transcriptional factor that promotes cell cycle and 
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tumor proliferation. 8q24/c-MYC restenosis is found in 7–15% of the activated B-cell-
like (ABC) subgroup of diffuse large B-cell lymphoma (DLBCL), and the reports 
are predominantly associated with extranodal localization [4–8]. B-cell lymphomas 
include follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone 
lymphoma (MZL). Tumor cells show a strict topographical and functional relationship 
with FDCs, included with reactive lymphoid and stromal cells [3, 9]. The FDC patterns, 
described for FL and MCL, are reminiscent of the distribution pattern of FCD mesh-
work seen in the GC or the mantle zone of the secondary lymphoid follicle, respectively 
[3, 9]. T cells migrate to B-cell-enriched follicles and germinal centers within secondary 
lymphoid organs to provide help to B cells. Correlation T and B cells within germinal 
centers are essential for B-cell differentiation into germinal center B cells and selection 
of mutated cells into memory B cells or memory plasma cells. Different stages of matu-
ration lead to B cell becoming a helper T cells and B follicular helper T (TFH) cells [10].
C-MYC translocation is characteristic of Burkitt’s lymphoma, where it is found 
in 80–90% of cases. In B-cell lymphoma 2 (BCL2) transgenic mice, it has been 
shown that polyclonal B-cell proliferation causes the growth of lymphoid follicles, 
but only 20% of mice develop monoclonal diffuse lymphomas after long latency. 
Long-term exposure to oncogene, progression from polyclonal to monoclonal dis-
ease, and appearance of the BCL2 transgenic mouse model suggests that lymphoma 
development depends on the secondary genetic events [8].
C-MYC is a strong transcription factor and promotes cell proliferation and growth, 
DNA replication, and protein biosynthesis [11]. Dysregulation of c-MYC is essential 
in the pathogenesis of a number of B-cell lymphomas but is rarely reported in T-cell 
lymphomas. C-MYC rearrangement is found in multiple B-cell lymphomas including 
Burkitt lymphoma, diffuse large B-cell lymphoma (DLBCL), and B-cell lymphoma 
unclassifiable, with features intermedia between DLBCL and Burkitt lymphoma 
(BCLU). In normal cells c-MYC is a highly regulated transcription factor that is involved 
in cell cycle regulation, cell metabolism, mitochondrial biogenesis, nucleic acid synthe-
sis, and apoptosis [12]. C-MYC expression is detected in a much higher proportion of 
DLBCL (30–50%) and is associated with concomitant expression of BCL2 in 20 to 35% 
of cases [8]. Most of these tumors do not carry c-MYC/BCL2 chromosomal altera-
tions and have been named “double-hit lymphoma.” Most studies use a cutoff of 40% 
c-MYC-expressing cells to define these cases; the cutoff for BCL2 expression has varied 
considerably in the literature, but a figure of 50% is recommended [8, 13–16].
Germinal centers (GCs) form in the center of the B-cell follicles of secondary 
lymphoid organs, interspersed within a network of stromal cells known as fol-
licular dendritic cells (FDCs) [17, 18]. In follicles that do not contain GCs (primary 
follicles), FDCs play an important role, helping B cells to cluster into compact, 
well-defined follicle [18–20]. FDC has a long-term retention of antigen within 
complement immune complexes in a form that can support affinity-dependent 
“testing” of immunoglobulin somatic hypermutation (SHM)-modified B-cell Ag 
receptors (BCRs) that occurs during GC selection [21, 22]. Adaptive immunity 
involves the development of antibodies in GCs through SHM in GC dark zones 
(DZs) and clonal selection in light zones (LZs) [22, 23].
The spleen, lymph nodes, and mucosal-associated lymphoid tissues constitute 
secondary lymphoid tissues that are located strategically to efficiently trap foreign 
antigens entering peripheral tissues and mucosal sites. In secondary lymphoid tis-
sues, activation of B cells and T cells by native and processed antigenic determinants 
represents the beginning of the GC reaction [24]. The B cells bind membrane-bound 
immunoglobulins (B-cell receptors (BCR)) and express Ag-derived peptides 
in major histocompatibility complex (MHC-II) molecules on their surface [6]. 
Secondary lymphoid tissues facilitate interactions between antigen-bearing dendritic 
cells (DCs), B cells, and T cells to initiate adaptive immune responses. B cells express 
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B-cell receptors (BCRs) on their cell membrane, and BCRs allow the cell to bind to a 
specific antigen and initiate an antibody response [18, 23, 25]. Despite these common 
features, differences in routes of antigen transport, lymphocyte trafficking, and 
unique cell populations determine the role of a specific secondary lymphoid tissue 
in immune responses to various foreign antigens. In the GCs, naive B cells can have 
clonal expansion, somatic hypermutation, and maturation [26, 27].
Germinal centers (GCs) are organized into two major zones: dark and light 
zones. The dark zone contains large centroblasts that are rapidly proliferating and 
undergoing somatic mutation. These cells grow to small nonproliferating centro-
cytes in the light zone, and binding antigen on follicular dendritic cells (FDCs) and 
development further depend on receiving signals from helper T cells [18, 22, 23, 28].
The activated B cells have two possibilities: (1) turnover into extrafollicular areas 
followed by proliferation and terminal differentiation into short-lived plasma cells 
that secrete antibody and (2) turnover into B-cell follicles followed by prolifera-
tion of GCs [27]. The mechanisms responsible for this remain poorly understood, 
although various studies suggest that the affinity of the BCR for the foreign antigen, 
the amount of antigen-receptor engagement, and the costimulatory signals received 
from T cells may all be involved. These observations suggest that the affinity 
maturation of the antibody response occurs in GCs, through the processes of clonal 
proliferation, somatic hypermutation, and selection [27].
T cells play a key role to induce B-cell proliferation and somatic hypermuta-
tion and to limit GC reactions. T cells in the germinal center activate helper T 
cells (CD4+CD57+CD25−) migrating in the germinal center to activate the B-cell 
zone-homing C-X-C chemokine receptor type 5 (CXCR5) [29, 30]. B cells primarily 
excrete interleukin 4 (IL-4). They begin in the paracortical T-cell area of IgD follicle 
expression, but T-cell maturation results in a characteristic follicular CD10+ immuno-
phenotype that has been acquired. Although the germinal center formation is intact 
in the presence of the FDC network, FDC plays a key role in the formation of memory 
B cell, and interaction is dependent on the expression of the tumor necrosis factor 
(TNF) family. The germinal center is not only created from different stages of B-cell 
maturation but also through the division of immunophenotypically different and 
functionally specialized T cells, dendritic cells, and subpopulations of stromal cells 
and their interactions. The antigen-stimulated B cells with the germinal center are 
highly mobile within the zone as well as between the dark and light zone [18, 23, 31].
In general, naive B cells in the central lymphatic system mature through the trans-
formation and proliferation of B cells toward plasma cells and B cells that produce 
antibodies. Malignant diseases may develop during such processes, and B-cellular 
neoplasms tend to imitate different stages of normal B-cell differentiation [1].
In the primary phase of differentiation, the progenitor of the B cell passes 
through renaming, and further development is followed by immunoglobulin genes 
(Ig) and occurs at naive B cells in peripheral lymphoid tissue or passes through apop-
tosis. Naive B cells can enter the primary follicle, forming a germinal center (GC), 
where mature CD10- and B-cell lymphoma 6 (BCL6) centroblasts expression mature 
[2]. Centroblasts continue maturing in centrocytes, which later co-express BCL2 
gene. Naive B cells can be directly developed in plasma cells. The germinal center is 
partially monitored by Bcl6 protein, which in humans is encoded by the BCL6 [32] 
and IRF4/MUM1 proteins, which is essential for further lymphocyte differentiation 
into plasma cells or memory B cell. On the other hand, antigen stimulation of lym-
phocyte can go toward apoptosis [2]. MUM1 is a lymphocyte-specific transcriptional 
factor of the interferon regulatory factor (IRF) family, included in the regulation 
of gene expression in response to interferon and other cytokines. MUM1 provides 
immunoglobulin gene expression in the final step of B-cell differentiation within 
germinal center light zones. At this stage Bcl-6 is downregulated [2].
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Secondary follicles are important for B-cell differentiation and maturation. B-cell 
differentiation begins via gene resection for the DJ region of the IgH gene. Each immu-
noglobulin molecule consists of two identical heavy chains and two identical light 
chains. This region represents the organization of heavy-chain locus. The locus includes 
variable (V), diversity (D), joining (J), and constant (C) segments. Within B-cell 
development, DNA recombination level joins a single D segment with a J segment; the 
fused DJ segment of a DNA molecule containing information coding for a protein or 
peptide sequence of this partially rearranged DJ region is then joined to the V segment. 
The introduction of region V into DJ results in VDJ coupling, and then the conversion 
successfully generates IGH protein chain. After the successful generation of the IgH 
gene, Ig light chains (IgL) are formed. The removal of IgL starts with light chain kappa. 
When the IgH and IgL genes are productive, B cells are called naive B cells because they 
are not exposed to the appropriate antigens and reside in the marginal zone of  the sec-
ondary follicle [4]. The cells that have not been exposed to antigens are known as naïve 
or virgin B cells and remain at the mantle zone until they are exposed to antigens [22]. 
According to the B-cell differentiation stage, B-cell precursor includes B lymphoblastic 
leukemia/lymphoma, while pre-GC neoplasms include cell lymphoma. GC B-cell 
tumors are follicular lymphoma, Burkitt’s lymphoma, Hodgkin’s lymphoma, and dif-
fuse large B-cell lymphoma (DLBCL). In the last stage of B-cell differentiation, post-GC 
neoplasms, including marginal zone lymphoma, mucosa-associated lymphoma tissue 
(MALT), lymphoplasmic lymphoma, chronic lymphocytic leukemia (CLL), plasma cell 
myeloma, and some cases of DLBCL, are developed [1, 22] (Figure 1).
The majority of B-cell lymphomas appear from germinal center (GC) B cells, 
but it is unclear to what extent B cells in lymphoma keep the functional dynamics of 
GC B cells or are blocked at a special stage of the GC reaction [20].
The germinal center is probably the source of many lymphomas. The germinal 
center reaction begins when antigens, with T-cell signals, activate centroblasts that 
migrate from the dark zone to the light zone and begin to express their antibodies 
Figure 1. 
B-cell differentiation and association of B-cell neoplasms [1].
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on the cell surface known as centrocytes. Then apoptosis begins and competes 
for survival signals derived from FDCs and TFH cells. Germinal center selection is 
dependent on the tendency of their surface antibody to the antigen and can enter 
into the light zone of germinal centers, which are morphologically centrocytes and 
which are indivisible B cells with a notched core. The action or process of reentering 
into the dark zone as centroblasts gives a chance for nonselected B- cell mutants to 
gain more mutations in order to improve affinity toward antigen. Interactions with T 
cells are to prevent the generation of autoreactive germinal center B cells [18, 23, 33].
During the germinal center reaction, two different modifications of the B-cell 
DNA change B-cell receptor: somatic hypermutation and switch-off recombina-
tion. Both require activation-induced cytidine deaminase (AID). IgM, IgA, or IgE 
recurrence of IgM, IgG heavy-chain recombination changes occur, while somatic 
hypermutations imply mutations in the immunoglobulin-variable region, region that 
produces a population of B cells with an increase (or decrease) affinity for a particu-
lar antigen. These genetic modifications are essential for normal immune response 
but also a source of DNA damage that can become pathological with lymphoma [8].
Mature B-cell neoplasms involve about 30 different entities, while DLBCL is the 
most common type of non-Hodgkin’s lymphoma (NHL), which accounts for about 
40% of all non-Hodgkin’s lymphomas (NHLs). B-cell lymphomas are identified by 
a combination of morphological features and recognizable immunophenotype [20]. 
A list of transcription factors that modulate the B-cell germinal center phenotype 
and where cell selectively express BCL6, and includes interferon-regulatory factor 
4 (IRF4). IRF4 co-bound with the transcription factors PU.1 (plays a critical role in 
the development of white cells), and B-cell-activating transcription factor (BATF) 
to Ets or activator protein 1 (AP-1) composite motifs, united with genes involved in 
B cell activation and the GC response [18, 20, 23].
CD5 is a transmembrane glycoprotein with expression on the surface of T cells 
and a subset of B cells. The absence of CD5 performs thymocytes hyperresponsive 
to stimulation through the T-cell antigen receptor (TCR) in vitro. CD5 can influence 
the developing thymocytes by acting as a negative regulator of TCR-mediated signal 
transduction [34]. The CD5 signature included downregulated extracellular matrix 
genes such as POSTN, SPARC, COL1A1, COL3A1, CTSK, MMP9, and LAMB3 and 
comprised upregulated genes including TRPM4 [35–38] (Figure 2).
Bcl6 protein suppresses many genes involved in plasma cell differentiation, cell 
cycle progression, and responses to DNA damage and cell death. One of these genes 
is the transcription factor Blimp-1, the main regulator of plasma cell differentiation 
that reduces gene expression of mature B cells. The transcription factors Blimp-1 
and IRF4 are essential for plasma cell generation. However, their function in mature 
plasma cells has remained elusive. B cells germinate center begins to differentiate 
plasma cells, monitored by interferon regulatory factor 4 (IRF4)/MUM1, whose 
transcription factor is needed for conversion to plasma cells. IRF4 increases the 
expression of Blimp-1 [39], and this growth is suppressed by BCL6, so differentia-
tion takes place in favor of plasma cells [25, 39].
The transcriptional repressor Blimp-1 originally cloned as a silencer of type I inter-
feron (IFN)-β gene expression controls cell fate decisions in multiple tissue contexts. 
Blimp-1 functional loss in 3D cultures of mammary epithelial cells (MECs) results in 
the accumulation of dsRNA and expression of type III IFN-λ [39] (Figure 3).
Chromosomal translocation in B-cell neoplasms is divided into three functional 
categories: proliferation, inhibition of differentiation, and antiapoptotic activity. 
These three categories are essential for understanding the mechanism of lymphoma-
genesis. For DLBCL with BCL6 gene translocation, Bcl6 protein expression is a side 
for post-GC staging cells, but it is not yet clear what signal is needed. It is clear that the 
antiapoptotic function must be present for BCL2, which is expressed at the post-GC 
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centers. There are indications that BCL6 has the function of protecting cells from 
terminal differentiation and shows epigenetic changes that are conserved from human 
hematopoietic stem/progenitor cells (HSPCs) to mature B cells. These results suggest 
that BCL6 may function in a “hit-and-run” role in lymphomagenesis [8].
Lymphomagenesis is a complex process that takes place in many steps, in which 
lymphocyte signal distortion, transcriptional regulation, and apoptosis lead to trans-
formation. Experiments suggest that distorted expression of casein kinase II subunit 
alpha (CK2alpha) creates predispositions for lymphoma development. Further 
experiments suggest that CK2alpha lymphomas monitor the panel of lymphocyte 
transcription factors such as, for example, activator protein 1 (AP-1) and nuclear 
factor-kappaB (NF-ĸB) [40, 41]. NF-ĸB represents a group of related homodimeric 
and heterodimeric transcription factors that can activate different target genes 
involved in proliferation, differentiation, immune response, cell growth, and 
survival. Among the molecules induced by NF-ĸB are the cytokines, chemokines, 
and effectors of the immune response. NF-ĸB participates in response to inflamma-
tory signals through T receptors, TNF receptors, and IL-1 receptors [40–42]. CREB is 
one of the best understood phosphorylation-dependent transcription factors (CREB) 
[16]. In effector T and B cells, immune receptor signals induce within minutes a 
rise of intracellular Ca++, the activation of the phosphatase calcineurin, and the 
Figure 2. 
B-cellular differentiation and lymphomagenesis ([25], p. 1418).
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translocation of NFAT transcription factors from cytosol to nucleus; the induction of 
NFATc1/αA takes place during the G1 phase of cell cycle [43, 44]. The NFAT signal-
ing pathway oversees different aspects of cellular functions; NFAT has a function 
like calcium sensor, including calcium signaling with other pathways involved in 
development and growth, immune response, and inflammatory response. The NFAT 
family of transcription factors regulates different cellular functions such as cell 
survival, proliferation, migration, invasion, and angiogenesis [44, 45].
TCF/LEFs are multifunctional proteins that use their sequence-specific DNA-
binding and context-dependent interactions to specify which genes will be regulated 
by Wnts. The TCF/LEF families have been shown to regulate the expression of specific 
genes, such as c-Myc and Cyclin D1 [46]. These transcription factors are interde-
pendent and closely linked with each other to form a network in the above signaling 
pathways, which regulate the entire process of osteoblast proliferation and differentia-
tion [14]. Normally, these factors appear to be involved in the physiological activation 
response of lymphocytes before controlling the growth of malignant cells [47, 48].
Proliferation, differentiation, and apoptosis are associated with different types of 
lymphoma and chromosomal translocations. Each lymphoma has a separate prolif-
eration of the site, which is most clearly described in the follicular lymphoma that 
proliferates in the follicle. Special chromosomal translocations are associated with 
Figure 3. 
Oncogene path for three subtypes of DLBCL ([25], p. 1421).
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each type of lymphoma. BCL1 translocation results in disturbed cell cycle regulation. 
BCL2 and API2-MALT1 have an antiapoptotic function [49]. API2-apoptosis inhibi-
tor 2-MALT1 (mucosa-associated lymphoid tissue lymphoma translocation gene 
1)-induced NF-kappaB activation may contribute to antiapoptotic action probably 
through NF-kappaB-mediated upregulation of apoptotic inhibitor genes [49].
2. Classification and pathogenesis of DLBCL
Non-Hodgkin’s lymphoma (NHL) classification is based on pathohistological 
findings. The history of classification of lymphoid neoplasms begins in the 1940s. 
Based on the advancement in knowledge, the work classification and Kiel have 
replaced the revised European-American Classification of Lymphomas, and it is a 
step ahead of the classification given by the WHO [8].
Classifications are an essential part of modern medicine, offering a consensus on 
the terminology and disease definitions to be used interdisciplinary both in research 
and clinical practice. Evolution of lymphoma classification includes numerous 
attempts from descriptive schemes, relying on morphology to strictly clinically ori-
ented stratifications proposed by hematologists, usually without significant interna-
tional acceptance. The classification of the WHO (Swerdlow et al. 2008) differs from 
the previous classifications in defining the real entities of the disease through mul-
tiple divisions. The new entities defined in this release include extended immunophe-
notypes and some gene information relevant to the classification. Panel antibody was 
selected based on morphological differential diagnosis and tumor location. DLBCL 
is a diffuse proliferation of large neoplastic B lymphoid cells of the same size or up 
to two times than the normal lymphocyte or extremely large as in macrophages. The 
origin of these cells are B cells of the germinating center and postgerminant cells [8]. 
DLBCL can occur in the form of nodal and extranodal diseases. Approximately 40% 
of patients are present with extranodal disease. Any tissue organ can be the primary 
site of DLBCL, but the gastrointestinal tract is the most common site [33].
Tumor cells are B large transformed lymphocytes, but the morphological picture 
of DLBCL is varied, and the predominant morphological cell type can distinguish 
six subtypes of DLBCL: centroblastic, immunoblastic, T lymphocyte/histiocyte rich, 
anaplastic, plasmablastic, and DLBCL with cells similar to Reed-Sternberg cells and 
expression of anaplastic lymphoma kinase (ALK) protein. Tumor cells are positive, 
as defined by the disease, on pan-B markers CD19, CD20, CD22, and CD79a, and the 
positivity of intracytoplasmic or surface immunoglobulin (Ig) markers is distinctly 
expressed as CD5, CD10, CD30, and CD45 markers. Numerous chromosomal abnor-
malities have been detected with DLBCL, but no specific diagnostic changes have 
been isolated. The most frequent changes are breaks of regions 14q32, 3p21, 3q27, 
22q12, 1q25, and 18q21 and additional chromosomes 7,9,12 and 4q31-35,13p13-14 and 
17p11-13,8,9. In 11–23% of cases, DLBCL with advanced clinical stage of the disease 
revealed nine regions of chromosomal amplification and isolated amplified genes 
with a potential role in the formation of lymphoma. The clinical significance of each 
individual change has not been established, but some changes are associated with 
advanced clinical stage or poorer response to therapy. The abovementioned chro-
mosomal abnormalities are generally not found as individual changes. The accu-
mulation of a greater number of abnormalities indicates the progression of genetic 
changes, which play an important role in the pathogenesis of DLBCL [8, 33].
3. The WHO classification which was revised in 2016
See Table 1.
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4. Prognostic markers in DLBCL
4.1 Gene expression profile (GEP)
Clinical and morphological differences in DLBCL suggest the biological sig-
nificance of subtypes, which may help in adapting the therapy to be defined. The 
development of DNA microarray techniques provided the ability to identify gene 
expression of the tumor with a new molecular entity and a molecular predictor 
essential for survival. DNA microarray can analyze thousands of sites of previously 
identified genes. DLBCL has been identified by several tumor markers associated 
with unfavorable outcome after therapy and which can be linked to tumor cells and 
normal B lymphocytes. Phenotypic cells resemble normal B lymphocytes, but the 
clinical course is completely different [50–52].
Gene expression profile has shown that DLBCL can be divided into two molecu-
lar entities that differ in the gene expression profile. Hans et al. have identified two 
subgroups of DLBCL [34, 52]. One subgroup was called germinal center B-cell-like 
(GCB) and has a characteristic gene expression of normal GC B cells, in about 50% 
of cases, and the second group was called activated B-cell-like (ABC). Type-3 group 
is defined as nonclassified cases. According to the GEP classification, the observed 
prognosis distinguishes two major subtypes after the chemotherapy. Patients with 
GCB lymphoma have a more favorable outcome in 5-year survival than patients 
in the ABC group (68% vs. 24%) [52]. The distinction between GCB and ABC 
Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS)
Germinal center B cell-like (GCB)
Activated B-cell-like (ACB)
T-cell/histiocyte-rich large B-cell lymphoma
Primary DLBCL of the central nervous system
Primary cutaneous DLBCL, leg type
Epstein–Barr virus (EBV) positive DLBCL, not otherwise specified (NOS)
EBV mucocutataneous ulcer
DLBCL associated with chronic inflammation
Lymphomatoid granulomatosis
Primary mediastinal (thymic) large B-cell lymphoma
Intravascular large B-cell lymphoma
ALK+ large B-cell lymphoma
Plasmablastic lymphoma
Primary effusion lymphoma
Human herpesvirus 8 (HHV8)+ DLBCL, not otherwise specified (NOS)
Burkitt lymphoma
Burkitt-like lymphoma with 11q aberration
High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 translocations
High-grade B-cell lymphoma, NOS
B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical
Hodgkin lymphoma
Table 1. 
The 2016 update of WHO classification of DLBCL: subtypes and related entities [8].
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subgroups and their effect on survival are independent of any clinical features of 
the disease, and these findings are further confirmed in other retrospective series 
with patients treated with chemotherapy [34, 42, 45–49].
In DLBCL, the ratio of BCL2-positive cases is highly variable, ranging from 24 
to 80% among the study population in the previous studies that used immunohisto-
chemistry (IHC); therefore, its prognostic relevance is controversial [16, 53–55].
Overexpression of the BCL2 is associated with poor prognosis [55]. ABC-DLBCL 
subgroup is characterized by transcription expression of the BCL2 gene [55], 
trisomy 3, and 18q21-q22 and loss of 6q21-q22 [56]. Activation of the antiapoptotic 
NF-ĸB signal pathway occurs at ABC but not at GCB DLBCL [56].
GCB DLBCL is characterized by frequent REL amplifications, BCL2 transloca-
tions, and ongoing somatic hypermutation of the immunoglobulin genes [56].
Immunohistochemistry studies have a significant role, although complexity in the 
expression and performance of the interpretation of findings is very complex. They are 
used in the prognosis of DLBCL and in the therapeutic advantage of using rituximab [52].
DLBCL is a common type of aggressive non-Hodgkin’s lymphoma with clear 
biological and clinical characteristics. Many studies have focused on the significance of 
internal tumor characteristics, such as the presence of proteins or the presence of gene 
expression and chromosomal translocation. Significant component of cell biology is 
inherited from non-transformed stem cells. Each of the B-cellular lymphoma inherits 
the traces of B-cell differentiation, although the extent to which this malignancy is 
maintained and the maintenance of molecular and physiological properties of normal 
B cells are not yet clear. Redistribution of immunoglobulin genes in DLBCL and other 
lymphomas carries mutations having somatic hypermutation characteristics, and the 
diversity of antibodies normally occurs only with the germinal center of the secondary 
lymphoid organ. This data suggest that DLBCL is generated from each of the germinal 
centers of the B cell or from the B cell at a later stage of differentiation [1, 25, 50, 52, 56].
4.1.1 Germinal center B-cell-like (GCB)
CB DLBCL appears to be generated from the normal germinal B cell, the 
translocation t (14, 18) involving BCL2 [54], and the amplification of c-REL on the 
chromosome 2p was detected in 45% GCB DLBCL, whereas it was never detected at 
ABC subtype [56]. This finding suggests that different subgroups represent differ-
ent diseases and the consequence is a different mechanism of malignant transfor-
mation and significantly different survival after chemotherapy. CD10 and BCL-6 
are considered as germinal center markers, while IRF4/MUM1 is expressed on 
plasma cells in atypical light zones of the germinal center. By morphological charac-
teristics, the center is uniform form monomorphic. Expressions CD10, BCL-6, and 
MUM1 are used to classify GCB and ABC lymphoma subtype [1, 25, 46, 50, 56].
Many factors of B-cell differentiation in the germinal center affect the expres-
sion of transcription factors. The key B-cell transcription factor is PAX5 (PAX5 is a 
nuclear protein that has the ability to bind to wild-type PAX5 target loci) [53] and is 
required for regulating many B-cell-specific transcription factors and for B-cellular 
development from the B stage to mature B cells. The transcription factor PU.1 is 
an E26 transformation-specific family transcription factor that is required for the 
development of the immune system. PU.1 functions at both early and late stages 
of lymphoid and myeloid differentiation [57], and the IRF involved with Blim1/
PRDM1 was isolated from the family in further regulation of the transcriptional 
factor BCL6, which is essential for the formation and maintenance of the germinal 
center. Translocation t (3q27) is included in BCL6 gene and is found in 20–40% 
diffuse lymphomas. IRF4/MUM1 expression is required for activation-induced cyti-
dine deaminase (AID) expression, which is important for two significant functions 
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of the germinal center, namely, somatic hypermutation (SHM) and AID-mediated 
class switch recombination (CSR) [58]. They depend on hierarchical expression 
and the common regulation of transcription factors. For example, BCL6 and IRF4/
MUM1 are expressed mutually exclusively in germinal center cells, but with DLBCL 
BCL6 and IRF4 / MUM1, they have co-expression [8, 59].
The Epstein–Barr virus (EBV) is the second factor associated with disturbed GCB 
regulation. EBV is associated with numerous lymphoid neoplasms including Burkitt’s 
lymphoma and classical Hodgkin’s lymphoma and posttransplant lymphoproliferative 
disease. The transformation that leads through EBV is capable of major negative selec-
tion in the germinal center. EBV/LMP2A induces escape of the defective B cells of the 
germinal center of the apoptosis and does not only offer an intriguing model of lym-
phomagenesis but also confirms the significant role of exogenous factors such as viruses 
involved in forming the response of the germinal center [60]. EBV latent membrane 
protein 2A (LMP2A) is expressed on the membranes of B lymphocytes and blocks B-cell 
receptor (BCR) signaling in EBV-transformed B lymphocytes in vitro. In vivo studies 
indicate that LMP2A allows B-cell survival in the absence of normal BCR signals [60].
CD10 expression is associated with a more favorable prognosis, and MUM1 is 
normally found on plasma cells and in a small part of the atypical spot zone in the 
germinal center and represents a marker for a non-germinal center [61].
Patients in this group have significantly better 5-year overall survival and survival 
without signs of disease activity after chemotherapy with combined drugs (68% for 
GCB vs. 24.7% for non-GCB with use of gene-expression profiling) [8, 52, 56].
4.1.2 Activated B-cell-like (ABC)
ABC-DLBCL is generated from the postgerminal center of B cells during plas-
macytic differentiation. ABC is characterized by frequent changes in chromosome 
arm 3p but not 3q [62]. ABC lymphoma has a subtype gene expression that has the 
properties of normal B cells that are activated over B-cell receptors.
Trisomy 3 is a common chromosomal aberration and is found in 26% of respon-
dents. The forkhead transcription factor (FOXP1) is the third most potentially 
monitored gene in trisomy 3. High FOXP1 expression can contribute to B-cell 
lymphomagenesis by promoting B-cell survival inhibiting plasma cell differentia-
tion. The small FOXP1 isoform (FOXP1-iso) is predominantly expressed in ABC-
DLBCL, and studying its oncogenic potential and transcriptional activity is directly 
compared to FOXP1-FL in DLBCL cell lines and primary human B cells [61–64].
ABC lymphomas have expression of the plasma cell genome, including tran-
scriptional factor XBP1, which is the regulator of immunoglobulin secretion. XPB1 
is a protein which in humans is encoded by the XPB1 gene located on chromosome 
22. The XBP1 protein is a transcription factor that regulates the expression of genes 
important of the immune system and in the cellular stress response. C-MYC is 
necessary and sufficient for activation of the IRE1/XBP1 pathway [65, 66].
The constituent part of the NF-κB activation causes ABC lymphoma with 
expressing the IRF4 transcription factor, and this may push them toward differen-
tiation in the plasma cells [42].
ABC lymphomas can obtain genetic changes that interfere with Blimp-1, thereby 
blocking full differentiation into plasma cells. The block in differentiation repre-
sents an early step in the pathogenesis of ABC subtypes, but the nature of the cell 
precursor is unclear. These lymphomas contain high activation-induced cytidine 
deaminase (AID) values, and their IgH genes have severe mutations. However, 
most ABC lymphomas did not undergo a recombinant trigger, and they have IgM 
expression, unlike most of the normal B cells of the germinal center and other GCB 
lymphomas [39].
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NF-ĸB is present as a latent, inactive, IĸB-bound complex in the cytoplasm. 
When a cell accepts any of a large number of extracellular signals, NF-ĸB quickly 
enters the nucleus and activates gene expression. Key step for controlling NF-ĸB 
activity is the regulation of the I kappa B kinase (IKK) [42, 55, 62].
Various genetic abnormalities activate CARD11 in ABC subtype lymphoma. 
In normal B cells, antigen-receptor-induced NF-kB activation requires CARD11, a 
cytoplasmic scaffolding protein. To determine whether CARD11 contributes to tumori-
genesis, we sequenced the CARD11 gene in human DLBCL tumors [67]. In about 10% 
of patients, CARD11 is an oncogene with acquired mutations that activate NF-κB and 
can prolong cell survival. Mutant CARD11 generates large protein aggregates in the 
cytoplasm, which represent possible NF-κB activation sites. The survival of lymphoma 
ABC with the wild-type CARD11 depends on B-cell receptors and kinases [67].
ABC lymphomas have expression of the plasma cell genome, including transcrip-
tional factor XBP1, which is the main regulator of immunoglobulin secretion. ABC 
lymphoma has presented expression of genes characteristic of mitogen-activated B cells 
in the blood and is associated with a worse prognosis [66]. ABC-DLBCL is characterized 
by gain of 3q, 18q, and 19q and loss of 6q and 9p21, and GCB DLBCL is characterized 
by gain of 1q, 2p, 7q, and 12q; the genomic imbalances characteristic of the CD5(+) and 
CD5(−)CD10(+) groups were similar to those of the ABC and GCB types [68].
Lymphoma ABC does not have one expression of the germinal center gene, but 
has gene expression that is normally present in B cells after B-cell receptor stimula-
tion. MUM1 is found on plasma cells at later stage B-cellular differentiation and is 
associated with the gene profile of activated B-cellular DLBCL. The presence of 
BCL2 and Cyklin D2 is adverse prognostic parameters. Polymorphic centroblasts 
and immunoblasts are more commonly present in activated B-cell DLBCL. This 
group is characterized by a group of genes that are characteristic of plasma cells, in 
part, added to the endoplasmic reticulum and Golgi’s proteins involved in secretion. 
There is a significantly higher percentage of patients in this group [69].
5. Conclusion
The contribution of GC selection to phenomena such as immunodominance and 
original antigenic guilt has also not been established and is likely to be of consider-
able interest. Answering these questions will be crucial to our quest to produce 
more broad and new medications and will undoubtedly bring novel insights into the 
general functioning of GC, as well as of the immune system in general.
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